Insulin Resistance & HSV-2

Why the USA curves diverge — and why the UK r value is so high:

The USA story has two distinct phases. In the first phase (1950s–1994), both insulin resistance and HSV-2 rose together, driven by the post-war food transition and the sexual revolution respectively. In the second phase (1994–2022), awareness campaigns, safer sex education, condom promotion, and antiviral treatment reduced new HSV-2 transmissions. Serological prevalence fell from 21.9% (1988–94) to 12.1% (2015–16) — while insulin resistance climbed without interruption from ~16% to ~39%. This behavioural decoupling is why the USA r value across the whole period is modest.

The UK pattern is different. Starting from a very low base (~3–4% in the 1970s), HSV-2 rose steadily through the same decades that insulin resistance climbed, giving a near-perfect r = 0.97. The UK never had the same sharp mid-1970s peak the USA experienced, so there is no equivalent reversal in the data.

Crucially, the r value here measures transmission trends — not severity. The biological relationship between insulin resistance and HSV-2 operates primarily through reactivation and disease burden, not transmission. The KORA cohort study found HSV-2-positive individuals with insulin resistance are 59% more likely to develop prediabetes than seronegative people — independent of age, BMI, and all other metabolic confounders. Elevated insulin also directly triggers reactivation of the latent herpes thymidine kinase gene, creating a vicious cycle: IR worsens HSV-2 outcomes, and HSV-2 worsens insulin signalling.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but other factors dominate.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. The UK value of 0.97 places IR firmly in this category. The USA divergence reflects the success of behavioural interventions in reducing sexual transmission — it does not diminish the metabolic relationship between IR and HSV-2 disease burden.

Insulin Resistance Questionnaire →

Mechanistic note: Insulin resistance and HSV-2 are linked through three documented pathways. (1) IRS-1 degradation: HSV-2 degrades insulin receptor substrate-1, directly impairing cellular insulin signalling and contributing to systemic insulin resistance. (2) AMPK suppression: the virus suppresses AMPK — the cellular energy sensor — which simultaneously promotes viral replication and fat accumulation. Restoring AMPK (e.g. through fasting or metformin) reduces both. (3) Reactivation loop: at supraphysiological insulin levels, insulin can directly reactivate the latent herpes simplex thymidine kinase gene, triggering viral reactivation. This bidirectional relationship means that reducing insulin resistance — through fasting, dietary quality, and exercise — is one of the most mechanistically coherent strategies for reducing HSV-2 reactivation frequency and long-term metabolic consequences of the infection.

Data sources

Many people with HSV-2 have at least one other insulin-resistance-driven condition. See the full picture — all 10 conditions, their r values, prevalence data, and 50-year rise figures in one place:  See all 10 conditions →

← Return to Start Your Remission Here